Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-22-018941

Chief Financial Officer bought 75,000 shares at $2.08 ($156,000)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Alspaugh Jonathan Chief Financial Officer 2022-03-11 Purchase +75,000 $2.08 $156,000 165,372 D
Open-market purchases · 75,000 sh · avg $2.08 · $156,000
Loading xslF345X03/doc4.xml…